Market Cap | 20.26B | P/E | 20.45 | EPS this Y | - | Ern Qtrly Grth | -93.90% |
Income | 27.88B | Forward P/E | - | EPS next Y | - | 50D Avg Chg | - |
Sales | 966.05B | PEG | - | EPS past 5Y | - | 200D Avg Chg | -11.00% |
Dividend | 102.00% | Price/Book | 0.03 | EPS next 5Y | - | 52W High Chg | -37.00% |
Recommedations | - | Quick Ratio | 1.17 | Shares Outstanding | 1.15B | 52W Low Chg | 5.00% |
Insider Own | 1.03% | ROA | 4.71% | Shares Float | 1.13B | Beta | 0.62 |
Inst Own | 58.44% | ROE | 3.32% | Shares Shorted/Prior | -/- | Price | 15.75 |
Gross Margin | 66.60% | Profit Margin | 1.72% | Avg. Volume | 830 | Target Price | - |
Oper. Margin | 11.76% | Earnings Date | Nov 7 | Volume | 39 | Change | 0.00% |
Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others segments. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopy systems, surgical microscopes, endoscope reprocessors, and maintenance services. The Therapeutic Solutions Business segment provides urology, gynecology, respiratory, ear, nose, and throat products; GI endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials, such as synthetic bone filler, and orthopedic equipment. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Tokyo, Japan.